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Abstract: The covalent binding of β-lactams to proteins upon 
photochemical activation has been demonstrated using an 
integrated approach that combines photochemical, proteomic 
and computational studies, selecting human serum albumin 
(HSA) as target protein and ezetimibe (1) as probe. The results 
have revealed a novel protein haptenation pathway by this 
family of drugs that is alternative to the known nucleophilic ring 
opening of β-lactams by the free amino group of lysine residues. 
Thus, photochemical ring splitting of the β-lactam ring following 
a formal retro-Staudinger reaction gives a highly reactive ketene 
intermediate that is trapped by the neighbouring lysine residues, 
leading to an amide adduct. For the investigated 1/HSA system, 
covalent modification of Lys414 and Lys525 residues, which are 
located in sub-domains IIIA and IIIB, respectively, occurs. The 
observed photobinding may constitute the key step in the 
sequence of events leading to photoallergy. Docking and 
Molecular Dynamics simulation studies provide an insight into 
the molecular basis of the selectivity of 1 for these HSA sub-
domains and the covalent modification mechanism. The 
computational studies also reveal a positive cooperative binding 
of sub-domain IIIB that explains the experimentally observed 
modification of Lys414, which is located in a hardly accessible 
pocket (sub-domain IIIA). 
Introduction 
Drugs containing the β-lactam ring (azetidinones) are the first 
choice for the treatment of a broad range of bacterial diseases. 
That is the case of the widely prescribed β-lactam antiobiotics, 
such as penicillins, cephalosporins and monobactams, which 
have saved millions of lives and whose discovery has been one 
of the most important achievements in the history of Medicine 
(Chart 1). Also relevant are β-lactamase inhibitors, such as 
clavams and carbapenems, which are used to block the most 
prevalent cause of antibiotic resistance in bacteria, thus the 
enzymatic inactivation of drugs by β-lactamases. In 2010, the 
international consumption of β-lactams made up 65% of the 
global antibiotics market.[1]  
Currently marketed β-lactams are responsible for inducing a 
variety of adverse reactions; allergy is probably the most 
important and can be manifested as pruritus, erythema, urticaria, 
dermatitis, fever, asthma or even anaphylactic shock.[2] The 
most frequently reported allergy problems are due to penicillins, 
with up to 10% of patients exhibiting hypersensitivity to these 
drugs, followed by cephalosphorins.[3] Less prevalent but also 
significant are the allergic processes due to carbapenems, 
clavams and monobactams (Chart 1).[4],[5] These allergic 
diseases are due to the interaction of β-lactam drugs with the 
immune system that has been mainly explained by the hapten 
hypothesis. It is based on the observation that small organic 
molecules do not induce an immune response unless they are 
covalently bound to a protein.[6] 
 
Chart 1. Chemical structures of some families of β-lactam antibiotics and 
inhibitors of antibiotic resistance that contain the β-lactam moiety.  
Actually, β-lactams have been used to prove such hypothesis, 
based on the high reactivity associated with the strained four 
membered ring that facilitates covalent binding to proteins 
through a nucleophilic attack by the amino groups.[7] In this 
context, the most widely studied β-lactam is benzylpenicillin, 
which is considered a reference model.[8] Opening of its four-
membered ring by a protein amino group leads to a 
benzylpenicilloyl adduct through formation of an amide linkage. 
Similar results have been reported for amoxicillin, the most 
prescribed member of the family.[9] The main structural 
difference between cephalosporins and penicillins is the nature 
of the ring to which the β-lactam is fused, a 6-member 
dihydrothiazine in the former and a 5-member thiazolidine in the 
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latter. This feature modifies the electrophilic properties of the 
carbonyl group and, therefore, its potential to react with 
proteins.[10] Comparatively, little is known about drugs containing 
a monocyclic β-lactam moiety, although the available chemical 
data suggest that they should be much less reactive towards 
amines and hence more reluctant to undergo covalent 
attachment to proteins. For the above reasons, the covalent 
binding of β-lactams to carrier proteins has been intensively 
investigated, paying attention to detection and identification of 
the products. 
Human serum albumin (HSA) is a carrier protein often employed 
for model studies. It is the most abundant protein in human 
plasma, complexing a wide variety of endogenous as well as 
exogenous ligands.[11] Thus, HSA has been considered as the 
main target protein in the haptenation by penicillins, and a 
number of studies have focused on characterization of 
penicilloyl-HSA adducts. Although the factors that determine 
which amino acids become modified by β-lactams are not fully 
established, lysine residues are clearly more reactive.[12] 
With this background, it appears relevant to explore whether 
photochemical activation of β-lactams may enhance covalent 
binding to proteins, a process that constitutes the key step in the 
sequence of events leading to photoallergy. This is an important 
issue, and the public health problem associated with 
photobiological risk has been recognized by the major regulatory 
entities (EMA, FDA, etc.), who have issued a set of guidelines 
for compulsory photosafety testing of new active compounds. 
In the present work, the photoinduced binding of β-lactam to 
proteins has been investigated using an integrated approach 
that combines photochemical, proteomic and docking and 
Molecular Dynamics (MD) simulation studies, selecting HSA as 
target protein and ezetimibe (1, Chart 2) as probe. This recently 
marketed drug contains a monocyclic β-lactam core and its main 
function is to decrease the plasma cholesterol levels, acting as 
selective absorption inhibitor in the small intestine and reducing 
in this way the amount of cholesterol normally available to liver 
cells. This mode of action is complementary to that of statins, 
and is recommended as a second line treatment.[13] Concerning 
its reactivity, previous studies on degradation of 1 in aqueous 
media describe slow rearrangement or hydrolysis of the four 
membered ring.[14] Being a monocyclic β-lactam, 1 could in 
principle undergo photochemical ring splitting to give reactive 
intermediates, whereas it should react only sluggishly with 
nucleophiles win the dark. Moreover, the photoreactivity of 1 
should increase in the presence of electron donors, such as the 
aromatic side chains of the Tyr or Trp units of HSA.[15] The 
obtained results indicate that 1 is indeed photolabile, giving rise 
to a reactive ketene intermediate that undergoes nucleophilic 
attack by Lys414 and Lys525, which are located in sub-domains 
IIIA and IIIB of HSA, respectively, leading to covalent adduct 
formation. In addition, the docking and MD simulation studies 
performed provide an insight into the molecular basis of the 
selectivity of 1 for these sub-domains of HSA and the covalent 
modification mechanism. 
 
Chart 2. Chemical structure of ezetimibe 1. 
Results and Discussion 
Photochemistry of 1 in the absence of protein. Due to the 
poor solubility of 1 in water, acetonitrile as well as a 9:1 (v/v) 
mixture of acetonitrile and water were employed as solvents. 
The results were similar, although the process was markedly 
faster at shorter wavelengths. Irradiation of 1 was performed at 
max = 300 and 254 nm, in a multilamp photoreactor. The course 
of the reaction was followed by 1H-NMR spectroscopy. After 
purification by column chromatography, imine 2[16] and lactone 
3[17] were separated from the reaction crude as the sole 
photoproducts (Scheme 1). The 1H- and 13C-NMR spectra of 
isolated 2 matched with those of a commercially available 
sample, while in the case of 3, they were compared with data 
reported in the literature.[17] The corresponding 1H and 13C-NMR 
spectra are shown in the SI (Figures S1-S4).  
The reaction mechanism is outlined in Scheme 1. The anilide 
moiety would undergo N-CO bond splitting from the excited 
state; subsequent C-C bond cleavage of the primary biradical I 
would afford the corresponding retro-Staudinger products, 
namely 2 and ketene II; the latter was not even detected, since it 
rapidly evolves to the stable lactone 3, through an intramolecular 
nucleophilic attack of the hydroxyl group to the ketene carbon. 
 
Scheme 1. Photoreactivity of 1 in acetonitrile. 






To gain deeper insight into the excited states involved in the 
process, absorption, fluorescence and phosphorescence 
spectroscopy measurements were carried out on 1. Thus, the 
absorption spectrum of 1 in MeCN (Figure S5 in SI) displayed a 
maximum at 285 nm and reached the UVB edge of the solar 
radiation. The fluorescence spectrum in the same solvent 
exhibited a maximum at 314 nm. From the intersection between 
the normalized emission (black trace, Figure 1) and excitation 
bands (red trace, Figure 1), a singlet energy of 97 kcal mol−1 
was obtained. In the phosphorescence spectrum, recorded in 
EtOH at 77 K (blue trace, Figure 1), the maximum was located 
at 400 nm; the triplet energy obtained from this emission curve 
was 80 kcal mol-1. Thus, since the reported value for bond 
dissociation energy of the N-CO bond is ca. 82 kcal mol−1,[18] 
thermodynamic requirements indicate that the initial N-CO bond 
cleavage should preferentially occur from the singlet excited 
state. 
 
Figure 1. Normalized fluorescence emission (black trace) and excitation (red 
trace) spectra of 1 at 1 × 10
-5
 M concentration, in MeCN, at T = 295 K, under 
air; phosphorescence emission (blue trace) of 1 at 2 × 10
-5
 M concentration, in 
EtOH, at T = 77 K, under air. 
Dark binding of 1 to HSA. Binding experiments were performed 
following an established methodology based on the 
displacement of site-specific fluorescent probes by non-emitting 
compounds, such as 1. For this purpose, dansylamide (DA) and 
dansylglycine (DG) were taken as site I and site II markers, 
respectively.[19] 
Selective excitation at 350 nm of DA/HSA or DG/HSA 
complexes gave rise to fluorescence emission centred at 480 or 
475 nm, respectively. Figures S6 and S7 in the SI show the 
emission changes observed upon addition of ibuprofen (IBP, site 
II probe) or warfarin (WAR, site I probe) to the DG/HSA and 
DA/HSA systems. As expected for a site II ligand, addition of 
increasing amounts of IBP to the DG/HSA solution (at 1/1 molar 
ratio) induced a decrease of its emission intensity. Thus, DG 
was displaced out of the protein, and consequently a weaker 
and red-shifted emission was observed. In the case of DA/HSA, 
a similar behaviour was observed with WAR as displacer. 
Experiments performed with 1 indicate that the drug possesses 
higher affinity towards site II. Although the binding constant 
value cannot be accurately determined due to the extremely low 
solubility of 1 in PBS, 1 clearly does not displace DG from site II, 
while IBU does. Interestingly, when DA is bound to site I, 1 binds 
free site II, which produces an allosteric effect that provokes a 
compression of site I and a parallel enhancement of DA 
fluorescence. Similar examples of allosteric effects can be found 
in the literature.[20] The trend is shown in Figure 2, a plot of I/I0 vs 
equivalents of ligand added, constructed with data from the 
fluorescence experiments that appear in Figures S6 and S7 in 
the SI. 
 
Figure 2. Variation of relative fluorescence intensity observed for probe-
albumin solutions (4 × 10
-5
 M, 1:1 molar ratio) at em= 480 nm for DA/HSA and 
475 nm for DG/HSA, upon addition of WAR, IBU or 1. 
From the above experiments, it can be inferred that the value of 
the binding constant of 1 to site II is lower than that of IBU and 
DG (that are in the range of 2-3 ×106).[21] Indeed, it is probably 
one order of magnitude lower, since DG is not displaced even 
after addition of four equivalents of 1. Concerning the 
stoichiometry of the complex, Job Plot experiments could not be 
performed, due to the poor solubility of 1 in PBS. However, it 
appears to be close to 1:1 (may be with some contribution from 
a 1:2 complex), since the fluorescence of DA in HSA increases 
until addition of ca. 1.3 equivalents of 1, and then reaches a 
plateau. 
Proteomic analysis of the photobinding of 1 to HSA. 
Formation of covalent photoadducts was investigated by 
proteomic analysis; these experiments would indicate precisely 
which (if any) amino acid(s) are covalently modified after 
irradiation of 1 in the presence of HSA. Thus, the photoreactivity 
of 1 within HSA was addressed by HPLC-nanoESI analysis. The 
procedure consisted on trypsin digestion to cleave peptide 
chains mainly at the carboxyl side of Lys or Arg residues (unless 
they are neighbour to a Pro residue), followed by HPLC-MS/MS. 
The process allowed obtaining information on the modified 






peptide sequence and characterizing the adduct. Full scan and 
fragmentation data files were analysed by using the Mascot® 
database search engine (Matrix Science, Boston, MA, USA) and 
by entering variable modifications that take into account the 
main possible residues (Lys) able to react with ketene II 
obtained after cleavage of the β-lactam ring. Sequence 
coverage was 94%. The results are shown in Figure 3, with the 
modified peptides indicated in red. 
The main result was identification of two adducts in 
414KVPQVSTPTLVEVSR428 and 525KQTALVELVQ534 (Figure 3), 
with an increment of 194 amu. The modification site of the two 
peptide sequences was assessed by tandem mass experiments 
on the trypsin digests. The ESI-MS/MS spectra and 
fragmentation pattern are shown in Figures S8 and S9. The 
MS/MS analysis of fragment ions 414KVPQVSTPTLVEVSR428 
and 525KQTALVELVQ534 showed that the modified amino acids 
are Lys414 and Lys525, respectively). Products resulting from 
transimination of imine 2 were not detected, even if they were 
specifically searched. However, their formation cannot be 
completely ruled out, since once formed, they would probably be 
hydrolysed under the trypsin digestion conditions. The lack of 
covalent binding of benzaldehyde to proteins when analysed in a 
similar manner has been described in a previous work.[22] 
 
Figure 3. Amino acid sequence obtained after irradiation of HSA/1 protein 
complex, with the non-matched amino acids in green. The modified peptides 
are in red, and the altered amino acid residues are yellow-highlighted. 
Computational studies. Docking and MD simulations. The 
results of our proteomic studies revealed that irradiation of the 
HSA/1 protein complex at 1:1 molar ratio causes the chemical 
modification in a similar proportion of Lys414 and Lys525, which 
are located in sub-domains IIIA and IIIB, respectively (Figure 4). 
The structure of HSA consists in three homologous helical 
domains, namely I-III, each of which is divided into two sub-
domains, A and B.[23] In addition, the experimentally observed 
additional mass of 194 of the lysine residues suggests that in 
both cases nucleophilic addition of their corresponding -amino 
groups to the generated ketene intermediate after UV irradiation 
takes place to afford the corresponding amide adducts (Figure 
5).  
 
Figure 4. Crystal structure of HSA complexed with palmitic acid (PDB code 
4BKE,
[23]
 2.35 Å). The three repeated domains IIII and each sub-domains 
AB are highlighted with different colors and labeled. The complex contains 
seven palmitic acid molecules, depicted in spheres. The side chain of Lys525 
and Lys414, which are located in sub-domains IIIB (red) and IIIA (cyan), 
respectively, are shown in sticks and labeled. 
 
 
Figure 5. Protein adduct resulting after irradiation of the HSA/1 protein 
complex. 
In an effort to understand in atomic detail the covalent 
modification mechanism and to gain insight into the molecular 
basis selectivity for sub-domains IIIA and IIIB, molecular docking 
and MD simulation studies were carried out, which is described 
below. The binding modes of 1 in sub-domains IIIA and IIIB of 
HSA were first studied by molecular docking using the program 
GOLD[24] version 5.2 and the available enzyme coordinates of 
the crystallographically determined HSA in complex with palmitic 
acid (PDB code 4BKE,[25] 2.35 Å). This structure was chosen 
because palmitic acid, in addition to domains I and II, also binds 
in sub-domains IIIA and IIIB (Figure 4). The positions of the 
palmitic acid molecules in each of the identified sub-domains 
were used to define the recognition site and the radius was set 
to 10 Å. Docking studies were independently carried out in sub-
domains IIIA and IIIB. Moreover, in order to assess the reliability 
of the postulated binding, MD simulation studies were then 
MKWVTFISLL FLFSSAYSRG VFRRDAHKSE VAHRFKDLGE ENFKALVLIA 
FAQYLQQCPF EDHVKLVNEV TEFAKTCVAD ESAENCDKSL HTLFGDKLCT 
VATLRETYGE MADCCAKQEP ERNECFLQHK DDNPNLPRLV RPEVDVMCTA 
FHDNEETFLK KYLYEIARRH PYFYAPELLF FAKRYKAAFT ECCQAADKAA 
CLLPKLDELR DEGKASSAKQ RLKCASLQKF GERAFKAWAV ARLSQRFPKA 
EFAEVSKLVT DLTKVHTECC HGDLLECADD RADLAKYICE NQDSISSKLK 
ECCEKPLLEK SHCIAEVEND EMPADLPSLA ADFVESKDVC KNYAEAKDVF 
LGMFLYEYAR RHPDYSVVLL LRLAKTYETT LEKCCAAADP HECYAKVFDE 
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SRNLGKVGSK CCKHPEAKRM PCAEDYLSVV LNQLCVLHEK TPVSDRVTKC 
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TALVELVKHK PKATKEQLKA VMDDFAAFVE KCCKADDKET CFAEEGKKLV 
AASQAALGL 






conducted with the highest score solutions obtained by docking 
for each sub-domain IIIA and IIIB. The monomer of the HSA-
IIIA/1 and HSA-IIIB/1 protein complexes in a truncated 
octahedron of water molecules obtained with the molecular 
mechanics force field AMBER[26] was employed. To get insight 
into the covalent addition mechanism, these simulation studies 
were carried out considering the two possible protonation states 
of Lys414 and Lys525. The results of these studies are 
discussed below.  
Binding of 1 and covalent addition to sub-domain IIIB  The 
results from 100 ns dynamic simulation showed that the 
proposed binding for 1 in sub-domain IIIB obtained by docking 
was reliable as this complex proved to be stable during the 
simulation. Analysis of the root-mean-square deviation (rmsd) 
for the whole protein backbone (C, C, N and O atoms) 
calculated in the complex obtained from MD simulations studies 
revealed that it varies between 1.53.4 Å (average of 2.2 Å) and 
is relatively low for sub-domain IIIB (0.81.6 Å and an average of 
1.2 Å) (Figure S10). These studies revealed that 1 would be 
anchored to sub-domain IIIB of HSA via four polar interactions 
involving the lactam carbonyl group and the two hydroxyl groups 
(Figure 6). Specifically, the ligand would establish: (a) an 
electrostatic interaction between its lactam carbonyl and the 
protonated ɛ-amino group of Lys525; (b) two hydrogen bonds 
between its secondary hydroxyl group and the main carbonyl 
group of Lys525 and the amide side chain of Asn405; and (c) a 
hydrogen bond between its phenol group and the carboxylate of 
Asp549. 
Three main reasons led us to consider that Lys525 would be 
protonated in the HSA-IIIB/1 complex: (1) the pKa of Lys525, 
calculated using the H++ Web server,[27] is 9.6; (2) comparison of 
the simulation studies with the two possible protonation states of 
Lys525 revealed that the ammonium group of the protonated 
Lys525 was located closer to the carbonyl group of 1 than the 
corresponding free amino group in the neutral Lys525; and (3) 
during the simulation, the protonated Lys525 establishes an 
electrostatic interaction with the carboxylate group of Glu518 
(Figure S11A). The latter residue would be therefore well located 
to deprotonate Lys525 to afford the required nucleophile for the 
covalent modification reaction. Comparison of the position of the 
ligand during the simulation (Figures S12AS12B) and the 
analysis of the variation of the relative distance between the 
atoms involved in the aforementioned polar interactions during 
the whole simulation revealed that the ligand is well fixed in this 
pocket and its conformation properly controlled by these 
residues (Figures S13AS13C). In particular, the hydrogen 
bonding interaction between Lys525 and the secondary hydroxyl 
group in 1 is stable during 89% of the simulation with an 
average distance of 2.8 Å. Moreover, the hydrogen bond of the 
phenol group of 1 with the carboxylate of Asp549 is observed 
during 76% of the simulation with an average distance of 2.7 Å. 
Another relevant interactions that contribute to the binding 
specificity of 1 to sub-domain IIIB would be the numerous apolar 
contacts within the pocket. Specifically, it would involve residues 
Phe507, Phe509, Ala528, Leu529, Leu532, Leu547, Phe551, 
Ala552, Leu547, and Met548 (Figure 6B). 
Three main reasons led us to consider that Lys525 would be 
protonated in the HSA-IIIB/1 complex: (1) the pKa of Lys525, 
calculated using the H++ Web server,[27] is 9.6; (2) comparison of 
the simulation studies with the two possible protonation states of 
Lys525 revealed that the ammonium group of the protonated 
Lys525 was located closer to the carbonyl group of 1 than the 
corresponding free amino group in the neutral Lys525; and (3) 
during the simulation, the protonated Lys525 establishes an 
electrostatic interaction with the carboxylate group of Glu518 
(Figure S11A). The latter residue would be therefore well located 
to deprotonate Lys525 to afford the required nucleophile for the 
covalent modification reaction. Comparison of the position of the 
ligand during the simulation (Figures S12AS12B) and the 
analysis of the variation of the relative distance between the 
atoms involved in the aforementioned polar interactions during 
the whole simulation revealed that the ligand is well fixed in this 
pocket and its conformation properly controlled by these 
residues (Figures S13AS13C). In particular, the hydrogen 
bonding interaction between Lys525 and the secondary hydroxyl 
group in 1 is stable during 89% of the simulation with an 
average distance of 2.8 Å. Moreover, the hydrogen bond of the 
phenol group of 1 with the carboxylate of Asp549 is observed 
during 76% of the simulation with an average distance of 2.7 Å. 
Another relevant interactions that contribute to the binding 
specificity of 1 to sub-domain IIIB would be the numerous apolar 
contacts within the pocket. Specifically, it would involve residues 
Phe507, Phe509, Ala528, Leu529, Leu532, Leu547, Phe551, 
Ala552, Leu547, and Met548 (Figure 6B). 
In an effort to obtain further details of the covalent modification 
of Lys525 by 1, the HSA/ketene protein complex and amide 
adduct were then explored by MD simulation studies. The 
results suggested that the capture of the ketene intermediate by 
nucleophilic attack of Lys525 must be very fast since this 
intermediate moves away quickly from the Lys525 vicinity. This 
was already observed during the minimization step, which is 
previous to the dynamic simulation. As shown in Figure 6C, the 
position of the resulting amide would be frozen by two hydrogen 
bonds involving the hydroxyl and NH groups of the amide adduct. 
In addition, the introduced chain in the ɛ-amino group of Lys525 
would be embedded in the aforementioned apolar pocket. 
 
 







Figure 6. Proposed binding mode of 1 in sub-domains IIIB (AC) and IIIA (DE) obtained by docking and MD simulation studies. (A) Overall view of the HSA-IIIB/1 complex. The 
main backbone of 1 is shown as yellow spheres while sub-domains IIIB and IIIA are highlighted in red and blue, respectively. (B) Interactions of 1 with sub-domain IIIB of HSA 
(gray). A snapshot after 80 ns is shown. (C) Detailed view of the HSA-IIIB/1 adduct. The binding mode of the covalently modified Lys525 (green) through the formation of an 
amide bond (yellow) is shown. Snapshot taken after 80 ns. (D) Overall view of the HSA-IIIA/1 complex. (E) Interactions of 1 with sub-domain IIIA of HSA. A snapshot after 100 ns 
is shown. (F) Detailed view of the HSA-IIIA/1 adduct. The binding mode of the covalently modified Lys414 (violet) through the formation of an amide bond (yellow) is shown.  
Hydrogen bonding and electrostatic interactions between the ligand and HSA are shown as blue dashed lines. Relevant side chain residues are shown and labelled.  
Binding of 1 and covalent addition to sub-domain IIIA  Our 
computational studies showed that 1 would be fixed to sub-
domain IIIA by three hydrogen bonds (Figures 6D and 6E). Two 
of them are direct strong contacts, one between the carbonyl 
group in 1 and the hydroxyl group of Ser489, and another one 
between the hydroxyl group in 1 and the main carbonyl group of 
Phe488. The analysis of the variation of the relative distance 
between the atoms involved in the aforementioned interactions 
revealed that they are very stable as they are present during 
89% of the simulation with an average distance of 2.8 Å 
(Figures S13DS13E). The third hydrogen bond, which would be 
mediated by a water molecule, would involve the phenol group 
in 1 and the main carbonyl group of Val456 (Figure 6E). On the 
contrary to Lys525, Lys414 seems not to be contributing to the 
binding of 1. Moreover, as for sub-domain IIIB, Lys414 would 
also be establishing an electrostatic interaction with Glu492 
(Figure S11B) and 1 would have numerous aliphatic interactions 
with the apolar residues within the pocket. Specifically, residues 
Leu387, Ile388, Tyr411, Val415, Leu430, Val433, Leu453, 
Val456, Leu460, Val418 and Phe488 would be engaged.  
As for sub-domain IIIB, the results from our MD simulations with 
the ketene intermediate suggested that this compound would 
also react rapidly with Lys414. Moreover, the resulting amide 
adduct would establish two hydrogen bonds involving the 
hydroxyl and the NH amide groups and the main carbonyl 
groups of Phe488 and Leu491, respectively (Figure 6F). In 
addition, the covalently modified Lys414 would be well 
embedded in the apolar pocket involving the aforementioned 
residues. 
Remarkably, the analysis of the rmsd of the whole protein 
backbone for the HSA-IIIA/1 complex revealed that it is 
significantly larger than for the HSA-IIIB/1 one with values 
between 1.55.1 Å (average of 4.0 Å) (Figure S10). Although the 
rmsd values involving sub-domain IIIB are low (0.81.6 Å and an 
average of 1.2 Å), it seems that the HSA-IIIB/1 complex would 
be more stable than the HSA-IIIA/1 one. Comparison of the two 
protein complexes clearly reveals that when 1 binds to sub-
domain IIIB it causes a large conformational change in this sub-
domain of up to 16 Å (Figure 7A). Similar findings were 






obtained for MD simulation studies carried out with the 
corresponding palmitic acid protein complexes (Figures 7B and 
7C). 
Thus, when the ligand binds to sub-domain IIIB it causes a large 
opening of this protein region, whereas the binding to sub-
domain IIIA leads to the opposite effect. This seems to be due to 
the interaction of the ligand in the interface between the two sub-
domains (Figure 6A) that causes a remarkable increase of the 
protein volume in this region and a dramatic reduction of the 
flexibility of sub-domain IIIB. The relevant conformational 
changes that HSA can undergo on binding several ligands, 
specifically in domains I and III, was also previously reported by 
Curry et al.[27] Thus, comparison of the crystal structures of 
HSA/myristic acid protein complex (PDB code 1BJ5,[28] 2.5 Å) 
with the wild-type HSA (PDB code 1AO6,[29] 2.5 Å) proved to 
have a rmsd value after superposition of 479 -carbon atoms of 
2.90 Å (Figure S14). Therefore, taking into account: (i) the 
similar proportion obtained for the covalent modification of 
Lys414 and Lys525 in the proteomic studies, (ii) the greater 
accessibility of sub-domain IIIB than IIIA and (iii) the higher 
stability of the HSA-IIIB/1 complex than the HSA-IIIA/1 one, we 
considered that the formation of a ternary complex rather than a 
mixture of binary complexes would be reasonable; this is 
evaluated below. 
 
Figure 7. (A) Comparison of the HSA-IIIB/1 (red) and HSA-IIIA/1 (green) complexes. Ligands are not shown for clarity. Note the large conformational change that undergoes sub-
domain IIIB when binding to 1. (B) Comparison of the HSA-IIIA/palmitic acid binary complex after minimization and prior simulation (grey) and after 100 ns of dynamic 
simulation (pink). (C) Comparison of the HSA-IIIB/palmitic acid binary complex after minimization and prior simulation (grey) and after 100 ns of dynamic simulation (orange). 
Note how the binding of palmitic acid to sub-domain IIIB causes the opening of this sub-domain of up to 11.4 Å, whereas the binding to sub-domain IIIA yields the opposite 
effect. (D) Overall view of the proposed ternary HSA/1 complex obtained by MD simulation studies. Sub-domains IIIA and IIIB are highlighted in blue and red, respectively, 
whereas the molecules of 1 are shown using yellow spheres. A snapshot after 60 ns is shown. (E) RMSD plots for the protein backbone (Cα, C, N, and O atoms) calculated in the 
three complexes [HSA-IIIA/1 (green), HSA-IIIB/1 (red) and HSA-IIIBA/1+1 (black)] obtained from MD simulations studies. 






Ternary HSA/1 complex. Taking into account that: (i) depending 
on whether 1 binds to the sub-domain IIIA or IIIB 
conformationally different complexes may be formed, and (ii) in 
order to assess the affinity of 1 to sub-domain IIIA or IIIB, two 
possible pathways should be evaluated for the formation of the 
ternary complex (Scheme 2). Thus, we explored the 
incorporation of 1 to the free sub-domain IIIB in the HSA-IIIA/1 
protein complex to afford the HSA-IIIAB/1+1 one (A) and the 
opposite situation to give complex B. The binding free energies 
of 1 in each sub-domain of complexes A and B were calculated 
using the MM/PBSA[30] approach in explicit water (generalized 
Born, GB) as implemented in Amber (Table 1).  
 
Scheme 2. Possible formation of the protein ternary complex. 
 






1 HSA-IIIA/1 43.6  0.2
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HSA-IIIA/PAL 43.9  0.5
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only the last 80 ns of the whole simulation were 
considered for the calculations; 
c
standard error of mean; 
d
PAL = palmitic 
acid. 
 
For the binary complexes, the results of our computational 
studies revealed that the affinity of 1, as well as that of palmitic 
acid to sub-domain IIIB is higher than to IIIA. More importantly, 
the binding of a second 1 molecule to the free sub-domain IIIA of 
HSA-IIIB/1 complex to afford complex B is 24.5 kcal more 
favorable than opposite case. In addition, our MD simulation 
studies also showed that the resulting complex is more stable 
than the HSA-IIIB/1 one (Figures 7D and 7E). In fact, for the 
complex A, after 60 ns of dynamic simulation the ligand is no 
longer interacting with sub-domain IIIB. Therefore, it seems that 
the conformational changes that the protein undergoes as a 
result of the interaction of the ligand with sub-domain IIIB 
enhance the incorporation of a second ligand molecule to the 
more hidden pocket, sub-domain IIIA. Thus, HSA seems 
capable of transporting two 1 molecules in domain III due to a 
“positive cooperative binding” of sub-domain IIIB. This effect 
explains the unexpected and efficient experimentally observed 
covalent modification of Lys414, which is located in a highly 
hidden pocket of HSA. 
Hence, once the ketene intermediate is generated by irradiation 
of the HSA/1 protein complex, covalent attachment would 
probably occur by nucleophilic attack of Lys525 and Lys414, 
which would be triggered by Glu518 and Glu492, respectively, 
acting as the general base (Scheme S1). The MD simulation 
studies carried out with the HSA/ketene intermediate in both 
sub-domains suggest that the ketene reacts rapidly with both 
lysine residues. 
Conclusions 
The results obtained in the present work constitute an 
unambiguous proof supporting that, in addition to the known 
nucleophilic ring opening of β-lactams by the free amino 
group of lysine residues, there can be an alternative protein 
haptenation pathway by this family of drugs. It consists on 
the photochemical ring splitting of the β-lactam ring 
following a formal retro-Staudinger reaction, to give a highly 
reactive ketene intermediate that is attacked by the 
neighbouring lysines. In the case of ezetimibe, a β-lactam 
drug with anti-cholesterol activity, selective photobinding to 
Lys414 and Lys525 of HSA is demonstrated by proteomic 
analysis, in agreement with the expectations from docking 
and MD simulation studies. The latter studies also show 
that the specificity of ezetimibe for sub-domains IIIA and 
IIIB is due to the formation of several strong hydrogen 
bonding interactions with residues: (i) Phe488, Ser489 and 
Val456 (for sub-domain IIIA) and (ii) Asp549, Asn405 and 
Lys525 (sub-domain IIIB) as well as numerous lipophilic 
interactions with apolar residues within those pockets. The 
nucleophilic attack of Lys525 and Lys414 to the ketene 
intermediate would be triggered by Glu518 and Glu492, 
respectively, acting as the general base. These 
computational studies also reveal that the unexpected and 
efficient covalent modification of Lys414, which is located in 
a quite hidden pocket (sub-domain IIIA), would be possible 
due to a positive cooperative binding of sub-domain IIIB. 
Thus, the interaction of the ligand with sub-domain IIIB 
seems to cause a large opening of the protein that would 
enhance the binding of a second ligand molecule in this 
less accessible internal region. Work is currently in 
progress, to investigate the possible generality of the novel 
haptenation route in the widely employed penicillins and 
cephalosporins antibiotics. 
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A Novel Pathway of Protein 
Haptenation by β-Lactams 
 
 
A new haptenation mechanism of β-lactams drugs, which constitute the key step in the sequence of events leading to photoallergy, has 
been identified. Selecting human serum albumin as target protein and ezetimibe as probe, the covalent modification of Lys414 and Lys525 
residues (located in sub-domains IIIA and IIIB) were identified. The process involves the photochemical ring splitting of the β-lactam ring of 
ezetimibe giving a highly reactive ketene intermediate that is trapped by the neighbouring lysine residues. 
 
 
